(NASDAQ: KROS) Keros Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.81%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 35.93%.
Keros Therapeutics's earnings in 2026 is $87,014,000.On average, 11 Wall Street analysts forecast KROS's earnings for 2026 to be -$71,422,820, with the lowest KROS earnings forecast at -$95,070,057, and the highest KROS earnings forecast at -$26,500,364. On average, 10 Wall Street analysts forecast KROS's earnings for 2027 to be -$79,211,245, with the lowest KROS earnings forecast at -$110,335,371, and the highest KROS earnings forecast at -$56,313,274.
In 2028, KROS is forecast to generate -$52,458,497 in earnings, with the lowest earnings forecast at -$66,085,284 and the highest earnings forecast at -$22,359,682.